Adrenal Crisis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Adrenal Crisis Market Outlook

Thelansis’s “Adrenal Crisis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenal Crisis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Adrenal Crisis Overview

Adrenal crisis (Addisonian crisis/acute adrenal insufficiency/bronze Addison disease) as a profound impairment of general health and at least two of the following conditions hypotension (systolic blood pressure 100mmHg), severe fatigue, vomiting or nausea, hyperkalemia, hypoglycemia, and hyponatremia triggering parenteral glucocorticoid administration. The risk factor associated with the adrenal crisis is diabetes insipidus, diabetes mellitus (type 1 and type 2), hypogonadism, adrenal hemorrhage, pregnancy, and polyglandular autoimmune syndrome 1 and 2. An adrenal crisis occurs when there is adrenal insufficiency, either primary or secondary. Primary adrenal crisis is characterized by high ACTH from the destruction of the adrenal gland and low cortisol. Secondary adrenal insufficiency is characterized by low cortisol and normal ACTH caused by decreased ACTH secretion from the pituitary. The tertiary cause includes the disruption of the hypothalamus, which affects the release of CRH and ACTH. In adrenal insufficiency, patients experience an acute stress event. They cannot adjust their usual dose of glucocorticoid therapy, causing their body cortisol stores to rapidly deplete, leading to an adrenal crisis as patients cannot produce cortisol.

• In the United States, the prevalence of primary adrenal insufficiency is 40-100 cases per million, with an incidence of 6 cases per million.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: